Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma (Q41457918)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 February 2015

Language	Label	Description	Also known as
English	Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma	scientific article published on 10 February 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Paul N Cheng

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Pierre Chan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Li Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Jimmy Yuen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Roberta Pang

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Sheung Tat Fan

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Denys N Wheatley

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Ronnie T Poon

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

publication date

10 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

33

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

496-504

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocell

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Deprivation of arginine by recombinant human arginase in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (H

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Pegylated arginase I: a potential therapeutic approach in T-ALL

1 reference

https://api.crossref.org/works/10.1007/S10637-014-0200-8

21 January 2018

Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion

1 reference

https://pubmed.ncbi.nlm.nih.gov/25666409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0200-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Dimensions Publication ID

0 references

release_zwjimr6uh5es7fq64emutpboki

1 reference

https://api.fatcat.wiki/v0/release/zwjimr6uh5es7fq64emutpboki

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25666409 AND SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41457918&oldid=2204551622"